CN Patent

CN114099496A — 含etc1002和依泽替米贝的组合及治疗方法

Assigned to Esperion Therapeutics Inc · Expires 2022-03-01 · 4y expired

What this patent protects

本发明涉及含ETC1002和依泽替米贝的组合及治疗方法。本文具体公开了包含固定剂量的ETC‑1002和依泽替米贝的组合物。本文还公开了用于使用固定剂量的ETC‑1002和依泽替米贝的方法。用途包括治疗受试者的心血管疾病或降低受试者的心血管疾病风险的方法。用途还包括治疗受试者的高胆固醇血症的方法。

USPTO Abstract

本发明涉及含ETC1002和依泽替米贝的组合及治疗方法。本文具体公开了包含固定剂量的ETC‑1002和依泽替米贝的组合物。本文还公开了用于使用固定剂量的ETC‑1002和依泽替米贝的方法。用途包括治疗受试者的心血管疾病或降低受试者的心血管疾病风险的方法。用途还包括治疗受试者的高胆固醇血症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN114099496A
Jurisdiction
CN
Classification
—
Expires
2022-03-01
Drug substance claim
No
Drug product claim
No
Assignee
Esperion Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.